Wockhardt Shares Soar 8% Following CDSCO Approval of Zaynich Antibiotic, Continuing Impressive Rally.
Wockhardt Ltd. has experienced a significant surge in its share price, climbing 7.87% to Rs 1,910.50 on Friday following a pivotal regulatory endorsement from India’s Central Drugs Standard Control Organisation (CDSCO) for its novel antibiotic, Zaynich (Zidebactam/Cefepime). This approval is noteworthy as it allows Wockhardt to import and market Zaynich, aimed at addressing complicated urinary tract infections (cUTI) along with Gram-negative bacteremia. The enthusiasm surrounding this news is reflected in the stock’s impressive nearly 12% gain over the past two trading sessions, underlining strong investor confidence in the company’s latest development.
The optimism is largely bolstered by the encouraging results from the pivotal ENHANCE-1 Phase 3 clinical trial, which established Zaynich as a formidable alternative to the standard treatment Meropenem. The trial demonstrated a remarkable 89% clinical cure rate in patients treated with Zaynich, compared to 68.4% for Meropenem, delivering a substantial treatment advantage of 20.6%. Particularly notable was Zaynich’s performance among high-risk bacteremia patients, achieving an astounding 89% response rate versus 44% for its competitor. The ability of Zaynich to successfully target metallo-β-lactamase (MBL)-mediated resistance positions the drug as a potentially revolutionary treatment for combating severe drug-resistant infections, greatly enhancing Wockhardt’s market appeal.
From a technical standpoint, Wockhardt’s stock remains on a bullish trajectory, having increased nearly 27% in the past month and a staggering 946% over the last three years, representing a near tenfold increase in investor wealth. Current technical indicators, such as a 14-day Relative Strength Index (RSI) of 72.3, suggest the stock could be approaching overbought conditions, which may lead to short-term profit-taking. However, with Wockhardt trading firmly above all eight key simple moving averages, the underlying momentum remains robust, indicating that further growth may still be on the horizon for this highly regarded pharmaceutical player.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)